Millennium Management LLC Buys 88,823 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Millennium Management LLC increased its stake in INmune Bio, Inc. (NASDAQ:INMB) by 43.9% in the fourth quarter, HoldingsChannel reports. The fund owned 291,327 shares of the company’s stock after purchasing an additional 88,823 shares during the period. Millennium Management LLC’s holdings in INmune Bio were worth $1,360,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Rhumbline Advisers lifted its stake in shares of INmune Bio by 16.9% in the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company’s stock valued at $78,000 after acquiring an additional 2,424 shares during the last quarter. Raymond James Financial Inc. bought a new position in INmune Bio during the 4th quarter valued at approximately $2,221,000. Renaissance Technologies LLC raised its position in INmune Bio by 73.3% during the 4th quarter. Renaissance Technologies LLC now owns 185,800 shares of the company’s stock valued at $868,000 after purchasing an additional 78,600 shares during the last quarter. Wells Fargo & Company MN raised its position in INmune Bio by 51.0% during the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock valued at $30,000 after purchasing an additional 2,155 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its position in INmune Bio by 71.6% during the 4th quarter. Dimensional Fund Advisors LP now owns 25,139 shares of the company’s stock valued at $117,000 after purchasing an additional 10,491 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

INmune Bio Stock Up 1.1%

INmune Bio stock opened at $7.27 on Wednesday. The company has a market capitalization of $167.09 million, a P/E ratio of -3.33 and a beta of 1.63. The stock’s 50 day moving average is $7.50 and its 200 day moving average is $7.06. INmune Bio, Inc. has a twelve month low of $4.32 and a twelve month high of $10.50.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, hitting the consensus estimate of ($0.43). The company had revenue of $0.05 million during the quarter. As a group, equities analysts expect that INmune Bio, Inc. will post -2.24 EPS for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Scotiabank upped their price target on INmune Bio from $22.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Tuesday, February 11th. Maxim Group upped their price target on INmune Bio from $22.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, February 13th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, INmune Bio has a consensus rating of “Buy” and an average price target of $22.80.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.